New dosing strategy aims to fight lung cancer in the brain
NCT ID NCT07348965
Summary
This study is testing if giving a higher dose of the lung cancer drug furmonertinib every other day is better at controlling cancer that has spread to the lining of the brain and spinal cord. It will enroll 42 adults with advanced lung cancer that has this specific spread and has worsened after initial treatment. The main goal is to see if this new dosing schedule is safe and effective, and to understand if it gets more drug into the fluid around the brain.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial Hospital of Chinese Medicine
RECRUITINGGuangzhou, Guangdong, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.